Based on our cumulative in vitro findings, we selected a sequential cytokine stimulation regimen with IL-2, followed by a combination of IL-2, IL-7, and IL-15, to generate AF-CAR T cells for therapeutic in vivo studies. Here, IL15 is linked to atrial fibrillation.